AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00130143
Drug: Ethyol (Amifostine)
RxNorm normalized name: amifostine Injection [Ethyol]
DrugBank: Amifostine (DB01143)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01086956
Drug: epidural infusion of saline, ropivecaine, or ropivacaine and sufentanil
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01025349
Drug: Bevacizumab, docetaxel, cisplatin
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab 8 mg/kg(over 60 minutes) on first day of first cycle, followed by 5 mg/kg on first day of the rest cycles, repeat every 2 weeks.~docetaxel 45 mg/m2(over 60 minutes) on day 1 of each cycle, repeat every 2 weeks.~cisplatin 50 mg/m2(over 4 hours) on day 1 of each cycle, repeat every 2 weeks.
Trial: NCT02118376
Drug: Exenatide
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5ug bid,Subcutaneous injection
Trial: NCT03304054
Drug: Amifampridine Phosphate
RxNorm normalized name: Amifampridine Phosphate
DrugBank: Amifampridine (DB11640)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: tablets equivalent to 10mg amifampridine, titrated to an efficacious and tolerable dose, 3 to 4 times a day
Trial: NCT02013206
Drug: erlotinib [Tarceva]
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erlotinib tablets taken orally once daily in the morning.
Trial: NCT03040011
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pudendal Nerve and Levator Muscle Injection. See additional information in study arm description.
Trial: NCT03040011
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pudendal Nerve and Levator Muscle Injection. See additional information in study arm description.
Trial: NCT03040011
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pudendal Nerve and Levator Muscle Injection. See additional information in study arm description.
Trial: NCT02727387
Drug: ADM
RxNorm normalized name: adMSC
DrugBank: Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic Origins (DB15729)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug used in the Induction phase in association with Vincristine, Ifosfamide, cyclophosphamide and Etoposide
Trial: NCT02727387
Drug: IFO
RxNorm normalized name: Epifoam
DrugBank: Pramocaine (DB09345)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug used in the Induction phase in association with Vincristine, Adriamycin, cyclophosphamide and Etoposide
Trial: NCT02727387
Drug: ETO
RxNorm normalized name: Ketone
DrugBank: Bis(5-Amidino-2-Benzimidazolyl)Methane Ketone (DB03213)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug used in the Induction phase in association with Vincristine, Ifosfamide, cyclophosphamide and Adriamycin
Trial: NCT02968160
Drug: Telmisartan 40mg, 80 mg
DrugBank: Telmisartan (DB00966)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02518958
Drug: RRx-001
RxNorm normalized name: RRx-001
DrugBank: RRx-001 (DB12060)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02518958
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01301521
Drug: water-soluble cinnamon extract (Cinnulin PF)
RxNorm normalized name: WATER SOLUBLE BASE
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Will take (by mouth) 1 gelatin capsule that contains 1 gram water-soluble cinnamon extract (Cinnulin PF) once a day for 12 months plus standard of care aggressive lifestyle therapy
Trial: NCT04022785
Drug: Azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV or SC
Trial: NCT04022785
Drug: BRD4 Inhibitor PLX51107
RxNorm normalized name: Brd4 inhibitor plx51107
DrugBank: PLX51107 (DB17543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT00005636
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00005636
Drug: pemetrexed disodium
RxNorm normalized name: Pemetrexed Disodium
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT03985982
Drug: Botulinum Toxin A
RxNorm normalized name: Botulinum toxin A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Injection, 20 Units divided in five 0.1 mL i.m injections into the glabellar area
Trial: NCT03223844
Drug: Dextroamphetamine Sulfate
RxNorm normalized name: Dextroamphetamine Sulfate
DrugBank: Dextroamphetamine (DB01576)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated oral administration of dexamphetamine 0.4mg/KG bodyweight four times.
Trial: NCT04098432
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nivolumab 3 mg/kg intravenously every two weeks untill disease progression or unacceptable toxicity
Trial: NCT03165240
Drug: BI 690517
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Film-coated tablet
Trial: NCT04188418
Drug: Fentanyl Citrate Buccal Tablet
RxNorm normalized name: fentanyl Buccal Tablet
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given transmucosally
Trial: NCT04188418
Drug: Morphine
RxNorm normalized name: Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT01678573
Drug: Treatment A: abiraterone acetate
DrugBank: Abiraterone (DB05812)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg/day tablet administered orally on Day 1 of each treatment period.
Trial: NCT01678573
Drug: Treatment B: abiraterone acetate
DrugBank: Abiraterone (DB05812)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg/day tablets administered orally on Day 1 of each treatment period.
Trial: NCT01678573
Drug: Treatment C: abiraterone acetate
DrugBank: Abiraterone (DB05812)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg/day tablets administered orally on Day 1 of each treatment period.
Trial: NCT01428037
Drug: Misoprostol vaginal Tablet 25 mcg
RxNorm normalized name: misoprostol Oral Tablet
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One tablet vaginal insert at 4 hrly interval with maximum of three doses
Trial: NCT00258232
Drug: irinotecan hydrochloride
RxNorm normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01981863
Drug: Epsilonaminocaproic acid
DrugBank: Aminocaproic acid (DB00513)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One group receives Epsilonaminocaproic acid, 10 gr IV bolus, followed by 1 gr/hr. Second group receives placebo.
Trial: NCT03271879
Drug: Empagliflozin at a dose of 10 mg/day
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Comparing empagliflozin versus placebo on the ventricular arrhythmia burden. This study encompass 4 periods for each study subject: screening period of 8 weeks, first treatment period of 8 weeks, washout period of 4 weeks and a second treatment period of 8 weeks in a cross-over design
Trial: NCT00616811
Drug: vildagliptin
RxNorm normalized name: Vildagliptin
DrugBank: Vildagliptin (DB04876)
FDA approved: no
EMA approved: yes
PMDA approved: no
Trial: NCT00616811
Drug: Sitagliptin
RxNorm normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT03788018
Drug: lidocaine and dexmedetomidine IV
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients received IV bolus infusion of lidocaine (2%) 1.5 mg/kg and dexmedetomidine 0.5 µg/kg diluted with normal saline to 20 ml in the LD group respectively, over 10 minutes before induction of anesthesia, followed by a continuous IV infusion at rate of lidocaine 1.5 mg/kg and dexmedetomidine 0.4 µg/kg made up to 20 mL every hour until 30 min before the end of operation, respectively.
Trial: NCT01791881
Drug: Botulinum Toxin Type A(Botox®)
RxNorm normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: 1.25U\~2.5U/site, Maximum dosage 12.5U\~60U/person
Trial: NCT03502330
Drug: APX005M
RxNorm normalized name: CD40 AGONISTIC MONOCLONAL ANTIBODY APX005M
DrugBank: Sotigalimab (DB16413)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APX005M is a humanized Immunoglobulin G (IgG) 1 agonistic monoclonal antibody that binds cluster of differentiation (CD) 40. APX005M is administered by intravenous infusion.
Trial: NCT01344681
Drug: Micafungin sodium
RxNorm normalized name: Micafungin Sodium
DrugBank: Micafungin (DB01141)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1. Treatment period (active treatment): an average 14 days~2. Dosage:~   - Study Drug: Micafungin sodium (mycamine ® injections 50mg/vial) 2 vials (100mg / day)~3. Administration Method:~   * Study Drug: 3-5 days after fever begins. Infusion one time a day (one hour). Termination of treatment after maintaining fever for three days or the recovery of neutrophils with no fever.
Trial: NCT01344681
Drug: Itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1. Treatment period (active treatment): an average 14 days~2. Dosage:~   - Active Comparator: Itraconazole (Sporanox ® injection) 200 mg 2 times(400mg / day)~3. Administration Method:~   * Active Comparator: 200 mg two times(400 mg) a day, total of 4 times for 2 days and then one times (200 mg) a day for 12 days. Termination of treatment after keeping fever for three days or the recovery of neutrophils with no fever.
Trial: NCT03502330
Drug: Cabiralizumab
RxNorm normalized name: Cabiralizumab
DrugBank: Cabiralizumab (DB15082)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabiralizumab is a humanized Immunoglobulin G (IgG) 4 monoclonal antibody directed against Colony stimulating factor 1 receptor (CSF1R). Cabiralizumab is administered by intravenous infusion.
Trial: NCT00801034
Drug: Potassium
RxNorm normalized name: Potassium
DrugBank: Potassium citrate (DB09125)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tablets, 5 tablets 2 times per day for 28 days
Trial: NCT04613557
Drug: Endoxan
RxNorm normalized name: Endoxana
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Preconditioning chemotherapy
Trial: NCT04613557
Drug: Fludara
RxNorm normalized name: Fludara
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preconditioning chemotherapy
Trial: NCT00132691
Drug: fluocinolone acetonide intraocular implant
RxNorm normalized name: fluocinolone acetonide Drug Implant
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: RETISERT™ (fluocinolone acetonide intravitreal implant) 0.59 mg is a sterile implant designed to release fluocinolone acetonide locally to the posterior segment of the eye at a nominal initial rate of 0.6 μg/day, decreasing over the first month to a steady state between 0.3-0.4 μg/day over approximately 30 months.
Trial: NCT00132691
Drug: oral corticosteroid with immunosuppressive agents as needed
RxNorm normalized name: Primatene with ephedrine Oral Product
DrugBank: Ephedrine (DB01364)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone
Trial: NCT03502330
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nivolumab is a humanized IgG4 monoclonal antibody directed against programmed cell death 1 (PD-1). Nivolumab is administered by intravenous infusion.
Trial: NCT02715024
Drug: Tamsulosin
RxNorm normalized name: Tamsulosin
DrugBank: Tamsulosin (DB00706)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT02715024
Drug: Solifenacin
RxNorm normalized name: Solifenacin
DrugBank: Solifenacin (DB01591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT02726022
Drug: Peginterferon alfa-2a
RxNorm normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: As per treating physician discretion and according to summary of product characteristics.
Trial: NCT02726022
Drug: Ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: As per treating physician discretion and according to summary of product characteristics.
Trial: NCT01466660
Drug: Afatinib
RxNorm normalized name: Afatinib
DrugBank: Afatinib (DB08916)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: afatinib once daily
Trial: NCT01466660
Drug: gefitinib
RxNorm normalized name: Gefitinib
DrugBank: Gefitinib (DB00317)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gefitinib once daily
Trial: NCT00309712
Drug: fenofibrate 160 mg and placebo
RxNorm normalized name: fenofibrate 160 MG
DrugBank: Fenofibrate (DB01039)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02743949
Drug: Vonoprazan
RxNorm normalized name: vonoprazan
DrugBank: Vonoprazan (DB11739)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Vonoprazan over-encapsulated capsules
Trial: NCT02743949
Drug: Esomeprazole
RxNorm normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Esomeprazole over-encapsulated tablets
Trial: NCT02743949
Drug: Esomeprazole Placebo
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Esomeprazole placebo-matching capsules
Trial: NCT01404793
Drug: Rocuronium
RxNorm normalized name: Rocuronium
DrugBank: Rocuronium (DB00728)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After insertion of the new liver and restoration of portal venous flow, 0.6 mg kg-1 rocuronium will be administered
Trial: NCT00198393
Drug: Gefitinib
RxNorm normalized name: Gefitinib
DrugBank: Gefitinib (DB00317)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 250 mg/day, until progression
Trial: NCT00198393
Drug: gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1250 mg/m² D1 and D8 (D1=D28, until progression)
Trial: NCT00198393
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75 mg/m² D1 (D1=D22, until progression)
Trial: NCT03806556
Drug: Tranexamic Acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV medication administered after patient meets inclusion/exclusion criteria
Trial: NCT04213404
Drug: Ribociclib
RxNorm normalized name: Ribociclib
DrugBank: Ribociclib (DB11730)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ribociclib 400mg, 600mg, or 200mg oral daily, D1-D21, 28 days a cycle
Trial: NCT04213404
Drug: Spartalizumab
RxNorm normalized name: Spartalizumab
DrugBank: Spartalizumab (DB14892)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spartalizumab 400mg ivdrip on D1, 28 days a cycle.
Trial: NCT02265484
Drug: Lactulose+Rifaximin +Bromocriptine
RxNorm normalized name: Rifaximin
DrugBank: Lactulose (DB00581)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01213147
Drug: clomiphene citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg per day oral for 7 days
Trial: NCT01213147
Drug: buserelin
RxNorm normalized name: buserelin
DrugBank: Buserelin (DB06719)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 µg Subcutaneous twice a day from cycle day 2 of menstrual cycle
Trial: NCT04155918
Drug: Group 1: AR882 Alone and in Combination with Febuxostat (FBX)
DrugBank: Febuxostat (DB04854)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: AR882 + Febuxostat, AR882 alone, Febuxostat alone
Trial: NCT04155918
Drug: Group 2: AR882 Alone and in Combination with Allopurinol (ALLO)
DrugBank: Allopurinol (DB00437)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AR882 + Allopurinol, AR882 alone, Allopurinol alone
Trial: NCT03109093
Drug: Blinatumomab
RxNorm normalized name: Blinatumomab
DrugBank: Blinatumomab (DB09052)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients will receive blinatumomab at a dose of 28 µg/day as continuous intravenous infusion at constant flow rate for four weeks, followed by a two-week infusion free interval, defined as one treatment cycle. Up to of four cycles will be performed.~In case of defined toxicities, the dose of blinatumomab may be reduced to 9µg/day.~Patients with an MRD relapse may qualify to receive additional treatment with blinatumomab.
Trial: NCT00685269
Drug: Eszopiclone
RxNorm normalized name: Eszopiclone
DrugBank: Eszopiclone (DB00402)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eszopiclone 3 mg QD
Trial: NCT03582865
Drug: Tamoxifen 20 mg
RxNorm normalized name: tamoxifen 20 MG
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tamoxifen 20 mg is a selective estrogen receptor modulator
Trial: NCT00144469
Drug: peginterferon alfa-2a
RxNorm normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00144469
Drug: rivavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02559934
Drug: SR-T100 Gel
RxNorm normalized name: SR 121463
DrugBank: SR 121463 (DB05455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3-0.5 g topical SR-T100 gel (containing 2.3% solamargine in Solanum undatum plant extract)
Trial: NCT05210517
Drug: Empagliflozin 25 MG
RxNorm normalized name: empagliflozin 25 MG
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 25 once daily one week treatment
Trial: NCT05210517
Drug: Benzbromaron
RxNorm normalized name: Benzbromarona
DrugBank: Benzbromarone (DB12319)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg once daily 1 one week treatment
Trial: NCT05210517
Drug: Empagliflozin 25 MG + benzbromarone 100 mg
RxNorm normalized name: benzbromarone
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: combined treatment once daily for one week
Trial: NCT00592163
Drug: ZIO-101-C (Darinaparsin)
RxNorm normalized name: Vitamin C
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose Escalation study, 200 mg - 900 mg, cumulative daily dose split to be taken BID 7 times a week (\>8 hours between doses) for 3 weeks followed by 1 week of rest
Trial: NCT00619424
Drug: pazopanib
RxNorm normalized name: Pazopanib
DrugBank: Pazopanib (DB06589)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral tablet administered daily in dosages of 400 - 800 mg.
Trial: NCT00619424
Drug: erlotinib
RxNorm normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral tablet taken daily in dosages of 100-150 mg.
Trial: NCT00619424
Drug: pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: IV chemotherapeutic agent administered every 21 days in dosages of 400-500 mg/m2
Trial: NCT05027126
Drug: Dexketoprofen 25 MG
RxNorm normalized name: dexketoprofen 25 MG
DrugBank: Dexketoprofen (DB09214)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical Form: Tablets Dosage: 25 mg Adminstration way: Oral
Trial: NCT02449889
Drug: highly purified human chorionic gonadotropin
RxNorm normalized name: human chorionic gonadotropin
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02449889
Drug: recombinant human chorionic gonadotropin
RxNorm normalized name: Recombinant human chorionic gonadotropin
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03197714
Drug: OPB-111077
RxNorm normalized name: OPB-111077
DrugBank: OPB-111077 (DB16630)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two dose schemas will be employed:~* Level 1: 200 mg daily~* Level 2: 250 mg daily
Trial: NCT01522521
Drug: AK156
RxNorm normalized name: Azelastine hydrochloride
DrugBank: Azelastine (DB00972)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: zoledronic acid (i.v.)/year + daily calcium and vitamin D for 2 years
Trial: NCT00797745
Drug: ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ribavirin 600 to 1400 mg daily (weight-based dosing) by mouth twice daily for up to 24 or 48 weeks
Trial: NCT00797745
Drug: SCH 900518
RxNorm normalized name: SCH 58500
DrugBank: SCH-58500 (DB17416)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCH 900518 100 mg tablets taken as 200 mg PO QD, 100 mg PO BID, 400 mg PO QD, or 600 mg PO QD for 12 weeks.
Trial: NCT00797745
Drug: ritonavir
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ritonavir 100 mg capsules taken as 100 mg PO QD or 100 mg PO BID for 12 weeks.
Trial: NCT00574730
Drug: CHOP/Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Six cycles of CHOP/Rituximab therapy at 21-day intervals. CHOP chemo will be administered on day 1 after rituximab.~Cyclophosphamide750mg/m2 IV, Doxorubicin 50mg/m2 IV, Vincristine 1.4mg/m2 (max 2mg) IV, Prednisone 100mg PO daily x 5 days Rituximab 375mg/m2
Trial: NCT00574730
Drug: PEG INTRON
RxNorm normalized name: Peginterferon Alfa-2b 150 MCG Multiple Routes Kit [PEG INTRON RP]
DrugBank: Peginterferon alfa-2b (DB00022)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pegylated Interferon-alpha 2mg/kg/week for 52 weeks
Trial: NCT01369641
Drug: Sodium Thiosulfate (STS)
RxNorm normalized name: Sodium Thiosulfate
DrugBank: Thiosulfuric acid (DB09499)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drops of STS will be added to the experimental ear only prior to initial cisplatin infusion.
Trial: NCT01369641
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin chemotherapy infusion in the dose range of 80-120mg/m2
Trial: NCT00521690
Drug: insulin detemir
RxNorm normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
FDA approved: yes
EMA approved: yes
PMDA approved: no